1. Home
  2. SLGL vs NEPH Comparison

SLGL vs NEPH Comparison

Compare SLGL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLGL
  • NEPH
  • Stock Information
  • Founded
  • SLGL 1997
  • NEPH 1997
  • Country
  • SLGL Israel
  • NEPH United States
  • Employees
  • SLGL N/A
  • NEPH N/A
  • Industry
  • SLGL Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • SLGL Health Care
  • NEPH Health Care
  • Exchange
  • SLGL Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • SLGL 69.1M
  • NEPH 57.2M
  • IPO Year
  • SLGL 2018
  • NEPH 2004
  • Fundamental
  • Price
  • SLGL $37.00
  • NEPH $5.61
  • Analyst Decision
  • SLGL Strong Buy
  • NEPH Strong Buy
  • Analyst Count
  • SLGL 1
  • NEPH 2
  • Target Price
  • SLGL $50.00
  • NEPH $5.50
  • AVG Volume (30 Days)
  • SLGL 16.8K
  • NEPH 85.3K
  • Earning Date
  • SLGL 11-14-2025
  • NEPH 11-05-2025
  • Dividend Yield
  • SLGL N/A
  • NEPH N/A
  • EPS Growth
  • SLGL N/A
  • NEPH N/A
  • EPS
  • SLGL N/A
  • NEPH 0.12
  • Revenue
  • SLGL $23,931,000.00
  • NEPH $16,684,000.00
  • Revenue This Year
  • SLGL N/A
  • NEPH $24.38
  • Revenue Next Year
  • SLGL $31.17
  • NEPH $10.16
  • P/E Ratio
  • SLGL N/A
  • NEPH $45.73
  • Revenue Growth
  • SLGL 264.86
  • NEPH 21.16
  • 52 Week Low
  • SLGL $4.01
  • NEPH $1.39
  • 52 Week High
  • SLGL $52.26
  • NEPH $5.98
  • Technical
  • Relative Strength Index (RSI)
  • SLGL 53.73
  • NEPH 57.90
  • Support Level
  • SLGL $38.01
  • NEPH $4.86
  • Resistance Level
  • SLGL $42.00
  • NEPH $5.97
  • Average True Range (ATR)
  • SLGL 3.42
  • NEPH 0.49
  • MACD
  • SLGL -0.95
  • NEPH -0.00
  • Stochastic Oscillator
  • SLGL 30.02
  • NEPH 67.12

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: